Phaseline

Companies › Aptabio Therapeutics

Aptabio Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Ophthalmology, Oncology, Metabolic and endocrine; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Isuzinaxib
Sphingosine-1-phosphate receptor 1 (S1PR1) modulator
S1PR1Phase 2Diabetic Kidney Disease (DKD)Jun 2027
ABF-101–Phase 1Age Related Macular Degeneration (ARMD)Nov 2027
APX-343A–Phase 1Advanced Solid CancerOct 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06962098IsuzinaxibPhase 2Diabetic Kidney Disease (DKD)Metabolic and endocrineJun 2027
NCT07330674ABF-101Phase 1Age Related Macular Degeneration (ARMD)OphthalmologyNov 2027
NCT07123415APX-343APhase 1Advanced Solid CancerOncologyOct 2028

Targets

S1PR1 (1)

Companies with the same targets

Novartis Viatris Innovation Boehringer Ingelheim Vanda Pharmaceuticals Bristol-Myers Squibb Pfizer Priothera SAS

Companies built like this

Priothera SAS Laekna Biojiva C Ray Therapeutics Innovent Biologics Technology Limited (Shanghai R&D Center)

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.